Obesity trials in Japan
36 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in JapanA Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
- Where
- Chiba-shi, Chiba, Fuchu-shi,Tokyo, Fukuoka, Himeji-shi, Hyogo, Hyōgo, Kanagawa, Kumamoto-shi, Kumamoto, Kyoto-shi, Kyoto, Matsumoto-shi, Nagano, Matsuyama-shi, Ehime, Morioka-shi, Iwate, Ono-shi Hyogo, Osaka-shi Osaka, Osaka-shi, Osaka, Ota-shi, Gunma, Suginami-ku, Tokyo, Takamatsu-shi, Kagawa, Tokorozawa-shi,Saitama, Tokyo, Toshima-ku,Tokyo, Wakayama-shi, Wakayama, Yao City, Osaka
- Age
- 45 years to 64 years
- People
- 8,500 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07861100 · EU 2026-525182-53-00 - Phase 3Taking peopleExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Where
- Aki-gun, Kashiwara-shi, Kitakyusyu-shi, Kumamoto, Matsuyama, Meguro-ku, Mitaka-shi, Mito, Naka, Shizuoka, Tsuchiura-shi
- Age
- 18 years to 99 years
- People
- 950 worldwide
- Run by
- Amgen
See details and how to joinNCT07684144 · EU 2025-524788-19-00 - Phase 3Taking peopleExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Where
- Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku, Yokohama
- Age
- 18 years to 99 years
- People
- 3,200 worldwide
- Run by
- Amgen
See details and how to joinNCT07684235 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Where
- Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
- Age
- 18 years and over
- People
- 1,980 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00 - No phaseEnrolling by invitationCities for Better Health Childhood Obesity Prevention Initiative
- Where
- Chiba
- Age
- 6 years to 13 years
- People
- 36,000 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06855563 - Phase 3Taking peopleAMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight
- Where
- Aichi, Bunkyo-ku, Tokyo, Chiba, Chiba-shi, Chiba, Chigasaki-shi, Chiyoda-ku, Tokyo, Chuo-ku, Tokyo, Fukuoka-shi, Fukuoka, Ibaraki, Kagawa, Kamakura-shi, Kanagawa, Kanagawa, Kawasaki-shi, Kitakyushu-shi, Fukuoka, Koriyama-shi, Fukushima, Kyoto-shi, Kyoto, Osaka, Osaka-shi, Osaka, Sapporo, Suita-shi, Tokyo, Yamato-shi, Yao City, Osaka
- Age
- 18 years and over
- People
- 400
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07822061 - Phase 3Not yet taking people in JapanAMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
- Where
- Sakai-shi, Osaka, Shinjuku-ku, Tokyo, Suita-shi, Tokyo
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07668401 - Phase 3Taking peopleA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Where
- Bunkyo-ku, Tokyo, Chiba-shi,Chiba, Chikushino-shi, Fukuoka, Fuchu-shi,Tokyo, Fukuoka-shi, Fukuoka, Higashiosaka-shi, Osaka, Himeji-shi, Hyogo, Hyōgo, Ibaraki, Kanagawa, Kasugai-shi, Aichi, Kofu-shi, Yamanashi, Kyoto-shi, Kyoto, Maebashi-shi, Gunma, Matsumoto-shi, Nagano, Miura-gun, Kanagawa, Morioka-shi, Iwate, Nagasaki, Osaka, Osaka-Shi, Osaka, Ota-shi, Gunma, Sapporo-shi, Hokkaido, Shinjuku-ku, Tokyo, Shizuoka, Takamatsu-shi, Kagawa, Tokyo, Tomakomai-Shi, Hokkaido, Toshima-ku,Tokyo, Uwajima-shi, Wakayama-shi, Wakayama, Yokohama-shi,Kanagawa
- Age
- 18 years and over
- People
- 5,610 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07567001 · EU 2025-523717-29-00 - Phase 1Not yet taking people in JapanA Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- Fukuoka, Sumida-ku, Toshima City
- Age
- 18 years to 65 years
- People
- 60
- Run by
- Eli Lilly and Company
See details and how to joinNCT07765511 - Phase 2Taking peopleA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Where
- Aichi, Ibaraki, Kanagawa, Kita-ku, Tokyo, Koriyama-shi, Fukushima, Saitama, Sendai-shi, Miyagi, Siga, Tokyo
- Age
- 18 years and over
- People
- 465 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06717698 · EU 2024-510846-15-00 - No phaseTaking peopleOsaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
- Where
- Sakai
- Age
- 20 years and over
- People
- 2,000
- Run by
- Osaka Metropolitan University
See details and how to joinNCT06694012